Browse by Person

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Jump to: Article
Number of items: 6.


Coleman, RE, Collinson, M, Gregory, W et al. (20 more authors) (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). Journal of Bone Oncology, 13. pp. 123-135. ISSN 2212-1374

Keane, M, Semeiks, J, Webb, AE et al. (27 more authors) (2015) Insights into the evolution of longevity from the bowhead whale genome. Cell Reports, 10 (1). pp. 112-122. ISSN 2211-1247

Coleman, R, Cameron, D, Dodwell, D et al. (13 more authors) (2014) Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. The Lancet Oncology, 15 (9). 997 - 1006. ISSN 1470-2045

Coleman, R, Hinsley, S, Bell, R et al. (7 more authors) (2013) Adjuvant therapy in early breast cancer with zoledronic acid (AZURE - BIG 01/04): Final efficacy analysis. European Journal of Cancer, 49 (Suppl 3). S5-S5. ISSN 0959-8049

Coleman, RE, Marshall, H, Cameron, D et al. (7 more authors) (2011) Breast-cancer adjuvant therapy with zoledronic acid. The New England Journal of Medicine, 365 (15). 1396 - 1405. ISSN 0028-4793

Coleman, R, Woodward, E, Brown, J et al. (11 more authors) (2011) Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment, 127 (2). 429 - 438. ISSN 1573-7217

This list was generated on Sun Oct 20 06:26:33 2019 BST.